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Abstract 
Purpose: To explore the effect of autoimmune response on the decreased cardiac function in patients 
with rheumatic mitral lesion following valve replacement.  
Methods: In this case-controlled study, 29 patients who had undergone valve replacement as a result 
of mitral lesion were enrolled (mean age = 48.7 years). Twenty healthy volunteers were selected as 
control (mean age = 47.5 years). Plasma levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), 
high –sensitivity C-reactive protein (hs-CRP) and echocardiographic indices of heart function in the two 
groups were investigated, respectively. Body mass index (BMI) was also calculated.  
Results: TNF-α, IL-6 and hs-CRP levels in plasma were significantly higher than those in controls (p < 
0.05; 22.23 pg/mL vs. 13.24 pg/mL, 53.42 pg/mL vs. 9.57 pg/mL, and 2.12 μg/mL vs. 0.97 μg/mL, 
respectively). The indices of left atrial diameter (LAD), left ventricular end-diastolic diameter (LDD) and 
isovolumetric contraction time (ICT) were significantly higher (p < 0.05; 4.72 cm vs. 3.78 cm, 4.85 cm 
vs. 4.37 cm, and 76.38 ms vs. 66.24 ms, respectively), but those of early diastolic velocity (Ea), late 
diastolic velocities (Aa) and ejection time (ET) were significantly lower (p < 0.05; 7.65 cm/s vs. 16.8 
cm/s, 5.56 cm/s vs. 12.9 cm/s, and 261.54 ms vs. 276.14 ms, respectively). Two-dimensional 
echocardiography obtained the same results. 
Conclusion: Valve replacement in patients with rheumatic heart disease (RHD) does not attenuate 
inflammatory response; rather, autoimmune response would keep affecting decreased heart function in 
RHD patients who have received mitral valve replacement. 
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Rheumatic fever (RF) is a delayed consequence 
of throat infection by Streptococcus pyogenes, 
and often affects susceptible untreated children. 
Nearly 30 - 45 % of the affected children could 
develop progressive and permanent valvular 
lesions, and leading to rheumatic heart disease 
(RHD). There are 15.6 million new cases of RHD 
per year worldwide, resulting in 233,000 deaths 
per year in developing countries [1]. The 
epidemiological data demonstrated that RHD is a 
crucial health problem. 
 
Currently, the mechanism of RHD is still far from 
being understood. The pathogenesis of RHD is 
complex, and potential reasons include cellular 
responses of Streptococcus pyogenes and 
autoimmune humoral responses toward human 
tissues [2]. The mechanism of molecular mimicry 
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is the process whereby T cells recognize self-
antigens, mainly the M protein of heart tissue, 
which shares homology with streptococcal 
antigens. Once activated, the T cells from RHD 
patients were able to recognize streptococcal M 
protein peptides as well as myocardium and 
valvular proteins, resulting in valvular lesions [3]. 
According to this pre-supposition, the process of 
autoimmune response should be eradicated after 
valve replacement by removing the valvular 
proteins and the heart function of RHD patients 
should be recovered. However, increasing 
clinical evidences indicated that the painful 
symptom still existed in most RHD patients after 
valve replacement. Therefore, mechanism of this 
phenomenon still remains uncertain.  
 
It has been noted that the autoimmune response 
status can be reflected by evaluating the 
cytokines’ levels [4]. A large number of studies 
have demonstrated that the production of 
inflammatory cytokines, including tumor necrosis 
factor (TNF)-α, interleukin (IL)-6 and high-
sensitivity C-reactive protein (hs-CRP), were 
increased after streptococcal antigen and 
pokeweed mitogen stimulation [5]. Therefore, the 
elevated levels of TNF-α, IL-6 and hs-CRP 
appear to play critical roles in triggering 
immunological and inflammatory reactions of 
RHD patients. In this study, it was hypothesized 
that the autoimmune response would persistently 
exist in RHD patients who have received heart 
valve replacement.  
 
Clinically, two-dimensional echocardiography is 
widely used as an effective approach to evaluate 
cardiac function heart function of patients with 
RHD [6], thus the echocardiographic indices 
were measured to evaluate the heart function, 
and the plasma levels of TNF-α, IL-6 and hs-
CRP were detected to investigate whether the 
autoimmune response affect the RHD patients 
receiving valve replacement or not. Also, the 
relationship between the plasma levels of TNF-α, 
IL-6, CRP and echocardiographic indices were 
analyzed to further explore the pathogenesis 
mechanism of the RHD patients who have 




Subjects and study protocol 
 
One thousand and five patients had undergone 
mitral valve replacement during January 2008 to 
May 2010 at the First Affiliated Hospital of Anhui 
Medical University. Of which, twenty-nine 
patients (mean age = 48.7 ± 7.2 years) were 
selected in this study. Rheumatic mitral lesions in 
the patients prior to operation were evaluated 
based on the clinical classification of New York 
Heart Association (NYHA). Six of the 29 selected 
patients were classified as NYHA class II, fifteen 
as class III, and eight as class IV. The operations 
were performed by the identical surgeons in the 
hospital.  
 
The instrumental prosthetic valves implanted 
were provided by Sorin Group (Italian). Heart 
function of the patients was recovered to NYHA 
class I after valve replacement. Additional 20 
healthy volunteers were recruited as the controls 
and were matched by age and gender (mean 
age = 47.5 ± 6.8 years). Subjects from either 
group were excluded if they had a history of 
cerebrovascular events, hyperlipidemia, venous 
thrombosis, diabetes, pulmonary diseases, 
disease of immune system, degenerative 
neurologic disorders, renal or liver disease, acute 
rheumatic fever, acute infection, inflammatory 
disease, malignancy, acute myocardial infarction, 
recent major surgery, trauma, and other chronic 
cardiovascular diseases such as hypertension 
and coronary heart disease.  
 
Informed consents were obtained from all study 
patients. Weight was measured to the nearest 
0.1 kg and calibrated with known weights and 
height was measured to the nearest 0.1 cm by 
using a stadiometer at the enrollment into the 
department of Cardiovascular Surgery in the First 
Affiliated Hospital of Anhui Medical University. 
Body mass index (BMI; kg/m2) was calculated.  
 
The patients continued treatment with 
digoxigenin, anticoagulant and diuretic for three 
months after the operation. The time course from 
the valve replacement surgery to the enrolment 
in this study was 3-29 months, and the average 
time was 15.3 months. The study protocol was 
approved by the Institutional Ethic Committee, 
Anhui Medical University (no. AHM-2007105#). 
 
Measurement of TNF-α and IL-6 
 
Blood samples of the patients were collected into 
an evacuated tube containing 3.8 % buffered 
sodium citrate. Plasma fractions were obtained 
by centrifugation for 10 min at 2000 rpm at room 
temperature, and aliquots were prepared and 
stored at −80 °C until the assay. Plasma levels of 
TNF-α and IL-6 were measured according to the 
manufacturer protocols of ABC-ELISA (R&D).  
 
Measurement of hs-CRP 
 
Hs-CRP was measured by latex-enhanced 
immunoturbidimetric assay with automatic 
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biochemistry analyzer (ADVIA Chemistry 
System, Bayer HealthCare AG, Leverkusen, 
Modular-P Switzerland). Both antiserum and 
standard substance were supplied by the DiaSys 




Both the patients and healthy volunteers 
underwent transthoracic two-dimensional and 
Tissue Doppler Echocardiographic examination 
by means of the Philips iE33 system with a 5.0 
MHz transducer. All echocardiographic 
examinations were assessed by an identical 
skilled cardiologist. Transthoracic 
echocardiographic measurements were obtained 
from the parasternal long-axis view by two-
dimensional targeted M-mode tracing.  
 
Left ventricular end-diastolic diameter (LDD) and 
left ventricular ejection fraction (LVEF) were 
measured to assess the left ventricles function, 
and left atrial diameter (LAD) was measured to 
reflect the function of the left atrium. LVEF and 
LDD were used as the most convenient and 
sensitive indices to estimate the left ventricular 
function [7]. Besides, LAD was used to assess 
the left atrium function [8].  
 
Using the 4-chamber view, a 2-mm sample 
volume was placed at the lateral corner of the 
tricuspid valve annulus and early diastolic (Ea) 
and late diastolic (Aa) myocardial velocities were 
obtained to evaluate the right heart function. 
Meanwhile, the indices of E/A, isovolumetric 
contraction time (ICT), isovolumetric relaxation 
time (IRT) and Tei index were measured to 
assess the right heart function. In addition, ECG 
tracings were performed.  
 
The indices of Ea, Aa, E/A, ET, ICT and IRT 
were demonstrated to be effective to assess the 
function of right heart [9, 10]. The Tei index was 
defined based on the formula: Tei = (ICT + 
IRT)/ET, to appraise a combined systolic and 




The results were expressed as mean ± standard 
error of the mean (SEM). Analysis of the plasma 
levels of TNF-α, IL-6 and hs-CRP and the indices 
of heart function between the cases and the 
controls were performed using Independent-
samples T test.  
 
P < 0.05 was considered statistically significant. 
All analyses were conducted by using statistical 




Plasma levels of TNF-α, IL-6 and hs –CRP in 
the groups 
 
The plasma concentrations of TNF-α, IL-6 and 
hs-CRP in each group were summarized in Table 
1. The levels of TNF-α, IL-6 and hs -CRP levels 
were found to be significantly higher in the cases 
than in the controls (p < 0.01; 22.23pg/L vs. 
13.24 pg/L, 53.42 pg/L vs. 9.57 pg/L, and 2.12 
μg/mL vs. 0.97 μg/mL, respectively). 
 
 
      Table 1: Characteristics of participants 
 
Variable Case (n = 29) Control (n = 20) P-value 
Age (years) 48.7 ± 7.2 47.5 ± 6.8 0.5604 
Female (%) 62.1 65 0.8343 
Height (cm) 167.1 ± 7.8 168.2 ± 8.1 0.6351 
Weight (kg) 61.8 ± 11.2 67.3 ± 11.7 0.0954 
BMI (kg/m2) 21.7 ± 4.1 23.1 ± 4.3 0.2552 
TNF-α (pg/mL) 22.23 ± 10.56 13.24 ± 8.76 0.003 
IL-6 (pg/mL) 53.42 ± 20.13 9.57 ± 8.14 <0.001 
Hs-CRP (μg/mL) 2.12 ± 1.98 0.97 ± 0.57 <0.001 
Ea (cm/s) 7.65 ± 1.78 16.8 ± 1.57 <0.0001 
Aa (cm/s) 5.56 ± 2.00 12.9 ± 1.97 <0.0001 
E/A 1.49 ± 0.47 1.62 ± 0.41 >0.05 
ICT (ms) 76.38 ± 15.04 66.24 ± 13.45 0.0195 
IRT (ms) 80.21 ± 16.21 75.13 ± 12.04 >0.05 
ET (ms) 261.54 ± 4.66 276.14 ± 19.72 0.0046 
LAD (cm) 4.72 ± 1.08 3.78 ± 0.89 0.0024 
LDD (cm) 4.85 ± 0.54 4.37 ± 0.58 0.0047 
EF (%) 59.72 ± 6.08 67.27 ± 6.25 0.0001 
Data are expressed as mean ± SEM 
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Figure 1: Figure 1A shows the levels of TNF-α, IL-6 
and hs-CRP and heart function in the cases and the 
controls; Figure 1B revealed the changes of 
echocardiography parameters of left heart function 
between the cases and the controls. In this study, the 
values of LAD and LDD were higher in the cases (p = 
0.0024 and 0.0047, respectively), but the value of 
LVEF was lower (p < 0.0001); Figure 1C demonstrates 
the changes of echocardiography indices of right heart 
function between the two groups. Compared to the 
controls, lower Ea, Aa and ET and higher ICT values 
were found in the cases (p < 0.0001, p < 0.0001, 
p=0.0046 and p=0.0195, respectively). No statistical 
difference was found in the indices of IRT, and Tei-
index between the two groups 
 
Comparison of two-dimensional echocardio-
graphy indices between the cases and 
control 
 
The echocardiography parameters of the left and 
right heart function in the two groups were shown 
in Figure 1A. Compared with the control group, 
the indices of LAD and LDD were higher in the 
cases  (p < 0.01, 4.72 cm vs. 3.78 cm and 4.85 
cm vs. 4.37 cm respectively), but the value of 
LVEF (%) was lower (p < 0.0001, Figure 1B). 
The indices of Ea, Aa and ET in the cases were 
significantly lower than those in the controls (p < 
0.05; 7.65 cm/s vs. 16.8 cm/s, 5.56 cm/s vs. 12.9 
cm/s, and 261.54 ms vs. 276.14 ms, 
respectively; p < 0.001, p < 0.001 and p < 0.01, 
respectively), but the index of ICT was higher (p 
= 0.0195, Figure 1C). The values for IRT and Tei 
index in the cases and the controls were similar 




In this study, it was found that the levels of TNF-
α, IL-6 and hs-CRP in plasma of the cases that 
received valve replacement were significantly 
higher than those in the controls. LAD and LDD 
represented the function of the left atrium, and 
LVEF indicated the function of the left ventricle. 
Echocardiography examination results indicated 
that the heart function was obviously poorer in 
the cases compared with the controls. The 
results also indicated that inflammatory process 
kept affecting the patients received valve 
replacement. Damaged valves would not be the 
exclusive source that induced immune reaction in 
the RHD patients. 
 
Rheumatic fever is autoimmune in nature and 
results from the production of auto-reactive 
antibodies and T-cells cross-reactive to the 
components of group A streptococcus and host 
tissues. It is evident that T lymphocytes are 
involved in the pathogenesis of rheumatic 
carditis, and the previous data supported the 
hypothesis that antibodies play important roles in 
the initiation of the disease at the valve 
endothelium [12]. The elevated levels of pro-
inflammatory cytokine are the direct evidences of 
the presence of the autoimmune reaction. 
Previous investigations demonstrated that 
overproduction of TNF-α promoted the induction 
of post-infection autoimmune response in RHD 
[13]. The previous data discovered that both the 
production in the plasma and the expression of 
TNF-α in the myocardium were significantly 
higher in patients with rheumatic mitral lesion 
[14]. Increased serum level of IL-6 occurred in 
the patients with congestive heart failure [15] and 
in the patients with RHD [16]. Additional IL-6 
might be secreted by the intralesional 
mononuclear cells from heart lesions 
predominantly in chronic RHD patients [17]. 
Moreover, increasing evidences showed CRP 
was a critical marker in assessing inflammation 
and tissue injury [18,19]. The plasma 
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concentration of hs-CRP was significantly higher 
in RHD [20,21] and could reflect progression and 
outcome of the rheumatic mitral lesion [22]. In 
this study, it was found that concentrations of 
TNF-α, IL-6 and hs-CRP in plasma were 
obviously higher in cases group than those in 
controls, suggesting excising primary mitral 
lesions did not obviously enable attenuate the 
autoimmune response triggered by 
Streptococcus pyogenes in the cases group.  
 
In previous investigations, there were few studies 
regarding immune reactions in postoperative 
patients. In this present study, we focused on 
whether immune reaction affects the outcome of 
valve replacement and improvement of cardiac 
function or not. We found that levels of TNF-a, 
IL-6 and hs-CRP in plasma were significantly 
higher in the case groups than those in healthy 
control groups. The over-production of cytokines 
could be secreted by T cells in response to 
autoimmune reaction which caused by the 
infection of β-hemolytic group A streptococci. 
Thus, it is advisable to conversely deduce that 
high levels of the TNF-a, IL-6 and hs-CRP could 
attribute to the active process of the autoimmune 
response in patients who undergone valve 
replacement. In the present research, it was 
demonstrated that immune reaction in RHD 
patients would occur even after valve 
replacement; another potential antigen that 
induced immune reaction in patients would be 
prosthetic valve. The mechanical prosthetic valve 
would act as an allotransplant to elicit the 
immune reaction [23]. Therefore, it was 
suggested that the valve replacement could not 
completely improve the cardiac function of RHD 
patients. Implementing anti-cytokines (such as 
anti-IL-6, anti-TNF-α and anti-hs-CRP) and 
administration of the inhibitor of p38MAPK could 
be the effective alternative modalities to prevent 
valve damage in RHD patients and to suppress 





The cardiac function of RHD patients did not fully 
recover after valve replacement due to 
synchronous influence of the autoimmune 
reaction. The elevated levels of plasma TNF-α, 
IL-6 and hs-CRP appear to be indices of 
autoimmune activities. And it seems that the anti-
autoimmune therapy administered to group-A 
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